Imatinib has drastically changed the outcome of patients with chronic myeloid leukemia (CML), offering the majority of patients a normal life span. More recently, the development of second, and third generation tyrosine kinase inhibitors and the advent of treatment discontinuation in CML made the management of these patients more challenging. Currently, three tyrosine kinase inhibitors are available in the first-line treatment of CML patients: imatinib, nolitinib and dasatinib. During several satellite symposia, hosted by Novartis during the 2015 annual meeting of the European Hematology Association (EHA), a panel of experts discussed the different aspects that need to be kept in mind when making treatment decisions in CML patients.

(BELG J HEMATOL 2015;6(3):85–7)